CenterBook Partners LP Sells 3,474 Shares of Natera, Inc. $NTRA

CenterBook Partners LP cut its holdings in Natera, Inc. (NASDAQ:NTRA) by 9.3% in the 3rd quarter, Holdings Channel.com reports. The firm owned 33,695 shares of the medical research company’s stock after selling 3,474 shares during the quarter. CenterBook Partners LP’s holdings in Natera were worth $5,424,000 as of its most recent SEC filing.

Other hedge funds have also recently bought and sold shares of the company. Main Management ETF Advisors LLC boosted its holdings in shares of Natera by 1.7% in the second quarter. Main Management ETF Advisors LLC now owns 4,398 shares of the medical research company’s stock valued at $743,000 after buying an additional 72 shares during the period. Yousif Capital Management LLC lifted its position in Natera by 4.5% in the 3rd quarter. Yousif Capital Management LLC now owns 1,682 shares of the medical research company’s stock valued at $271,000 after acquiring an additional 72 shares in the last quarter. Gries Financial LLC boosted its stake in Natera by 4.0% in the 3rd quarter. Gries Financial LLC now owns 1,904 shares of the medical research company’s stock worth $306,000 after purchasing an additional 74 shares during the period. LRI Investments LLC increased its holdings in Natera by 15.4% during the 3rd quarter. LRI Investments LLC now owns 578 shares of the medical research company’s stock worth $93,000 after purchasing an additional 77 shares in the last quarter. Finally, Blue Trust Inc. raised its stake in shares of Natera by 23.1% in the 3rd quarter. Blue Trust Inc. now owns 431 shares of the medical research company’s stock valued at $69,000 after purchasing an additional 81 shares during the period. 99.90% of the stock is currently owned by institutional investors and hedge funds.

Natera Trading Up 2.4%

NASDAQ NTRA opened at $211.25 on Wednesday. The firm has a market capitalization of $29.22 billion, a P/E ratio of -92.25 and a beta of 1.64. The firm’s fifty day moving average price is $229.23 and its two-hundred day moving average price is $200.54. Natera, Inc. has a 1 year low of $125.38 and a 1 year high of $256.36.

Insider Activity

In related news, CEO Steven Leonard Chapman sold 4,725 shares of the firm’s stock in a transaction dated Tuesday, February 3rd. The shares were sold at an average price of $230.77, for a total value of $1,090,388.25. Following the completion of the sale, the chief executive officer directly owned 123,156 shares in the company, valued at approximately $28,420,710.12. This trade represents a 3.69% decrease in their position. The sale was disclosed in a document filed with the SEC, which is accessible through the SEC website. Also, insider Solomon Moshkevich sold 1,639 shares of the business’s stock in a transaction that occurred on Tuesday, February 3rd. The stock was sold at an average price of $230.77, for a total value of $378,232.03. Following the transaction, the insider directly owned 137,847 shares in the company, valued at approximately $31,810,952.19. This trade represents a 1.18% decrease in their position. The SEC filing for this sale provides additional information. Insiders sold a total of 450,787 shares of company stock valued at $105,376,360 in the last 90 days. 5.63% of the stock is owned by company insiders.

Analyst Upgrades and Downgrades

A number of research firms recently issued reports on NTRA. BTIG Research increased their price objective on Natera from $230.00 to $260.00 and gave the stock a “buy” rating in a report on Friday, December 5th. Guggenheim raised their price target on shares of Natera from $230.00 to $270.00 and gave the stock a “buy” rating in a research note on Monday, January 5th. Piper Sandler lifted their price objective on shares of Natera from $220.00 to $230.00 and gave the company an “overweight” rating in a report on Tuesday, November 11th. Stephens increased their target price on shares of Natera from $197.00 to $235.00 and gave the stock an “overweight” rating in a report on Thursday, November 13th. Finally, JPMorgan Chase & Co. lifted their price target on shares of Natera from $250.00 to $260.00 and gave the company an “overweight” rating in a research note on Monday, December 15th. One analyst has rated the stock with a Strong Buy rating, thirteen have given a Buy rating, three have assigned a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat, Natera presently has a consensus rating of “Moderate Buy” and an average target price of $249.20.

About Natera

Natera is a global diagnostics company that develops and commercializes cell-free DNA and other genetic testing technologies for clinical applications. The company focuses on three principal areas: reproductive health (including non-invasive prenatal testing and carrier screening), oncology (tumor-informed assays for minimal residual disease and recurrence monitoring), and organ transplantation (cell-free DNA tests to detect allograft injury). Natera combines laboratory testing, proprietary bioinformatics, and clinical reporting to deliver personalized genetic information to clinicians and patients.

Key product offerings include Panorama, a non-invasive prenatal test that screens for fetal chromosomal abnormalities and select single-gene conditions; Horizon carrier screening for inherited conditions; Signatera, a personalized, tumor-informed assay used for detecting minimal residual disease and monitoring treatment response in cancer patients; and Prospera, a donor-derived cell-free DNA test used to assess the risk of organ rejection.